Sickle Cell Disease
Pipeline by Development Stage
Drug Modality Breakdown
Sickle Cell Disease is a ~$118M Medicare Part D market that is consolidating around one dominant player with emerging competitive alternatives.
Key Trends
- OXBRYTA (voxelotor) dominates with 86% of hemoglobin polymerization inhibitor share
- P-selectin blockers and iron chelators address complications rather than core pathology
- Hydroxyurea generics declining as newer mechanism drugs gain adoption
Career Verdict
SCD is a high-opportunity niche for specialists willing to focus on rare disease—strong job growth, high clinical stakes, and potential for meaningful patient impact, but limited overall market size may constrain long-term advancement in some roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | OXBRYTA (voxelotor) | Pfizer | $101M | 86% | PEAK | Stable | 11.4yr |
| 2 | ADAKVEO (crizanlizumab) | Novartis | $7M | 6% | PEAK | Stable | |
| 3 | JADENU (deferasirox) | Novartis | $9M | 8% | PEAK | Stable | 8.5yr |
Drug Class Breakdown
Market leader, stable growth
Supportive care, modest adoption
Anti-inflammatory approach, niche positioning
Career Outlook
StableSCD is a specialized, high-stakes therapeutic area with strong clinical unmet need and committed specialty pharma investment, but limited total addressable market constrains rapid career growth. Success requires deep expertise in rare disease commercial strategy, patient advocacy, and health economics; generalists moving into SCD should expect to develop highly specific domain knowledge. The field offers meaningful work on life-altering therapies and access to tight-knit clinical communities.
Breaking In
Enter SCD as a specialist through clinical operations or medical affairs roles at Novartis or Pfizer, where you'll gain deep disease knowledge; use that foundation to branch into commercial strategy or market access.
For Experienced Professionals
Experienced pharma professionals should target leadership roles in patient-centric programs or payer negotiations, where rare disease expertise commands premium valuation; consider lateral moves into gene therapy or cell therapy pipelines where SCD knowledge is transferable.
In-Demand Skills
Best For
Hiring Landscape
SCD-focused hiring is concentrated among top-tier pharma companies with broader rare disease portfolios (Novartis 647 jobs, Pfizer 556 jobs across all indications, but only modest direct SCD headcount). Commercial roles dominate (1,118 jobs across pharma) followed by manufacturing and R&D. Median salary for medical affairs and clinical operations ($302K–$307K) exceeds R&D ($224K), reflecting premium placement of patient-centric specialty roles.
Top Hiring Companies
By Department
Medical Affairs and Clinical Operations roles command premium compensation in SCD; however, absolute job counts are limited, so career advancement depends on moving into broader rare disease or oncology portfolios.
On Market (3)
Approved therapies currently available
Competitive Landscape
66 companies ranked by most advanced pipeline stage
+36 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 5,221 patients across 50 trials
Voxelotor Brain Oxygenation and Neurocognitive Study
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
Open-Label Extension of Voxelotor
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)
A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Open-Label Extension Study to Pioneer Study 6058-SCD-101
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Biotin-Acridine Red Cell Exchange Kinetics
Early Screening and Treatment of Heart Complication in Sickle Cell Disease
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia
Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
A Study of IMR-687 in Subjects With Sickle Cell Disease
Crizanlizumab for Treating COVID-19 Vasculopathy
Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
Related Jobs in Rare Diseases
Director, Biostatistics
Global Value Access Strategy Director
Market Research & Insights Associate Director
Senior Specialist, Site Supply Chain Planning
Director, Pharmaceutical Development
Director, Analytical Chemistry
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.